Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR).

Kyoichi OkishioRyo MoritaJunichi ShimizuHaruhiro SaitoHiroshi SakaiYoung Hak KimOsamu HatajiMakiko YomotaMakoto NishioKeisuke AoeOsamu KanaiToru KumagaiKayoko KibataHiroaki TsukamotoSatoshi OizumiDaichi FujimotoHiroshi TanakaKeiko MizunoTakeshi MasudaToshiyuki KozukiTakashi HakuHiroyuki SuzukiIsamu OkamotoHirotoshi HoshiyamaNobumichi YadaYuichiro Ohe

Published in: ESMO open (2021)

Based on Japanese real-world data, the effectiveness and safety of nivolumab were confirmed regardless of age.

Keyphrases

electronic health record
cross sectional
middle aged
big data
machine learning
data analysis